Using image-based learning to localize proteins

10 March 2020|

In the latest issue of the Journal of Cell Biology, the Andrews lab acquired >1.2 million confocal micrographs of EGFP fusion proteins localized at key cell organelles in murine and human cells from which morphology and statistical features were measured. Machine learning algorithms they developed that use these features to permit automated assignment of the localization of other proteins and dyes in both cell types with higher accuracy […]

Activation of cell death by Bad.

New details on how cells activate programmed cell death

28 February 2020|

In the latest issue of Molecular Cell, the Andrews lab provide the first evidence that the complexes of Bcl-2 family proteins, which regulate mitochondrial outer membrane permeabilization and thereby cell death, are not necessarily dimeric.  Instead Bad binds a pre-existing membrane bound hetero-trimer consisting of a dimer of Bcl-XL and one tBid, promoting an allosteric change in the complex that lifts tBid away from the membrane enabling the […]

Dr. David Andrews’ latest discovery highlighted

12 April 2019|

By Matthew Pariselli

In a new eLife paper, Dr. David Andrews, a senior scientist at Sunnybrook Research Institute, and his lab show how an interaction between proteins promotes cancer cell survival.

Andrews, who is also a professor in the department of biochemistry at the University of Toronto, discovered that Bim, a pro-cell-death protein, binds to anti-cell-death proteins at two sites, rendering it “double-bolt locked.” Previously, it was thought there was […]

An image of malignant lymphocytes from a patient with chronic lymphocytic leukemia. Image: Dr. Sina Oppermann.

Andrews’ lab identifies potential new drug combinations for chronic lymphocytic leukemia

8 July 2016|

In a paper recently published in the journal Blood, Dr. David Andrews’ group used high-content screening to test 320 kinase inhibitors and identify ones that, when given in combination with venetoclax, can overcome resistance to the drug. Venetoclax inhibits the anti-apoptotic protein Bcl-2 and received breakthrough status from the U.S. Food and Drug Administration this year. It is available in the U.S. to treat patients with chronic lymphocytic […]

CIHR Foundation Grants Awarded to Four Faculty Members

15 July 2015|